## Review setup

- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the supplied abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors use molecular dynamics simulations, including locally enhanced sampling (LESMD), single ligand-protein conformation MD, and ensemble docking, to propose that thiosemicarbazone (TSC) molecules NPC and DPT bind to the p53 cancer mutant R175H at specific sites, with NPC targeting the L2-L3 loop region near the zinc-binding site and DPT targeting alternative sites, and that these interactions stabilize the mutant toward a wild-type-like conformation.
- **Visible evidence base** Abstract text only; no quantitative simulation data, structural figures, or methodological details are provided
- **Missing materials affecting confidence** Full manuscript, simulation parameters, force field details, convergence criteria, docking scores, binding free energy calculations, structural coordinates, and any experimental validation

## Reviewer

- **Overall assessment** The abstract presents a plausible computational hypothesis that TSC ligands may bind to p53R175H at distinct sites, but the evidence base is too limited to assess the validity of the claims. The reported interactions are qualitative and lack quantitative support. The central claim that TSC binding stabilizes the mutant toward a wild-type-like state is not substantiated by any comparative data. The work may be of interest to computational cancer biology researchers, but the case is not established from the supplied material.
- **Who would be interested in the results, and why** Computational biophysicists and medicinal chemists studying p53 reactivation strategies, particularly those focused on mutant protein stabilization by small molecules. The proposed binding sites could inform future drug design efforts, though experimental validation would be required to attract a broader cancer biology audience.
- **Major strengths** The study addresses a clinically relevant target, p53R175H, and explores a mechanistically interesting hypothesis involving direct ligand binding rather than only zinc metallochaperone activity. The use of multiple computational approaches, including LESMD and ensemble docking, suggests methodological ambition.
- **Major Concerns** 
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness
  - **Claim pointer** The abstract claims that NPC binds the L2-L3 loop region forming hydrogen bonds with HIS175, pi-sulfur bonds with TYR163, and pi-alkyl linkages with ARG174 and PRO190, and that DPT targets alternative sites.
  - **Evidence pointer** Abstract text; location not provided
  - **Concern** The abstract provides no quantitative metrics for these interactions, such as occupancy, distance distributions, or interaction energies. It is unclear whether these contacts are stable across the simulation or transient artifacts. No docking scores or binding free energy values are reported to support the claim of favorable binding.
  - **Why it matters** Without quantitative interaction data, the reader cannot judge whether the proposed binding modes are physically meaningful or statistically robust. The claim of specific residue-level contacts requires evidence of persistence and energetic favorability.
  - **Resolution test** Provide interaction occupancy percentages, average distances with standard deviations, and computed binding free energies (e.g., MM-PBSA or similar) for each ligand-receptor complex, with comparison to a control or decoy system.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Scientific importance
  - **Claim pointer** The abstract states that the similar structural characteristics of TSC-bound p53R175H complexes with wild-type p53DBD are attributable to involved interactions that favor binding free energy contributions.
  - **Evidence pointer** Abstract text; location not provided
  - **Concern** The claim that TSC binding induces a wild-type-like conformation is central to the therapeutic relevance, but no structural comparison metrics are provided. The abstract does not report root-mean-square deviation (RMSD) to wild-type, per-residue fluctuation changes, or any conformational ensemble analysis.
  - **Why it matters** The therapeutic hypothesis depends on the mutant adopting a wild-type-like fold. Without comparative structural data, the claim is unsupported and the significance of the binding events is unclear.
  - **Resolution test** Show RMSD or contact map comparisons between TSC-bound p53R175H and wild-type p53DBD, with statistical significance testing across simulation replicates.
  - **Concern ID** R1-M3
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness
  - **Claim pointer** The abstract implies that the combination of LESMD, single ligand-protein MD, and ensemble docking is sufficient to identify potential binding sites.
  - **Evidence pointer** Abstract text; location not provided
  - **Concern** No methodological details are given, including force field parameters, simulation length, number of replicas, solvent model, temperature coupling, or convergence assessment. The LESMD approach is mentioned but not described in terms of how the 10 TSC conformations were generated or how the ensemble was validated.
  - **Why it matters** Reproducibility and reliability of molecular dynamics results depend critically on these parameters. Without them, the technical soundness of the simulations cannot be evaluated.
  - **Resolution test** Provide full simulation protocols in the methods section, including software version, force field, water model, ion concentration, simulation time, and convergence metrics such as block averaging or RMSD stabilization.
- **Minor Comments** 
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Readability for nonspecialists
  - **Affected element** Abstract clarity
  - **Evidence pointer** Abstract text
  - **Issue** The abstract uses terms such as LESMD and ensemble docking without brief explanation, which may hinder nonspecialist readers.
  - **Required correction** Add a short parenthetical description of LESMD and ensemble docking in the abstract or introduce them more clearly in the main text.
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Scientific importance
  - **Affected element** Contextual framing
  - **Evidence pointer** Abstract text
  - **Issue** The abstract does not state how these findings differ from or extend prior computational studies of TSC-p53 interactions, limiting the perceived novelty.
  - **Required correction** Include a sentence in the introduction or discussion that explicitly contrasts the present approach and findings with earlier work.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Technical soundness
  - **Affected element** Interaction nomenclature
  - **Evidence pointer** Abstract text
  - **Issue** The term pi-sulfur bond is used without defining the geometric criteria used to identify it, which may be ambiguous.
  - **Required correction** Define the distance and angle cutoffs used for pi-sulfur and pi-alkyl interaction detection in the methods.
- **Technical failings that need to be addressed before the case is established** R1-M1, R1-M2, R1-M3
- **Assessment against Nature-style criteria** 
  - Originality: Moderate. The application of LESMD to TSC-p53R175H binding is somewhat novel, but the general concept of computational ligand binding to p53 mutants is not new.
  - Scientific importance: Potentially high if the wild-type-like stabilization claim is validated, but currently unsubstantiated.
  - Interdisciplinary readership: Limited to computational biologists and medicinal chemists; broader appeal would require experimental correlation.
  - Technical soundness: Not assessable from the abstract due to missing methodological and quantitative details.
  - Readability for nonspecialists: The abstract is reasonably clear but uses specialized terms without definition.
- **Recommendation posture** Currently not established from the provided evidence. The hypothesis is interesting and worth pursuing, but the abstract alone does not provide sufficient quantitative or methodological support. A revised manuscript with full simulation details, interaction metrics, and structural comparisons could change this assessment.

## Risk / unsupported claims

- The claim that NPC forms specific bonds with HIS175, TYR163, ARG174, and PRO190 is unsupported without quantitative interaction data.
- The claim that TSC-bound p53R175H complexes resemble wild-type p53DBD is unsupported without structural comparison metrics.
- The claim that the identified sites have druggable properties is speculative and not supported by any pocket analysis or druggability scoring.
- The overall therapeutic implication of mutant stabilization is not assessable from the supplied material.